| JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis |
53 |
| A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis |
39 |
| The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults |
37 |
| Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial |
35 |
| Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis |
34 |
| Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment |
31 |
| Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis |
30 |
| Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis |
30 |
| Janus kinases to jakinibs: from basic insights to clinical practice |
26 |
| Osteoarthritis: the genesis of pain |
25 |
| The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist |
25 |
| Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients |
23 |
| Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study |
21 |
| Large-vessel giant cell arteritis: diagnosis, monitoring and management |
21 |
| Gout: state of the art after a decade of developments |
20 |
| Physiological effects of modulating the interleukin-6 axis |
20 |
| Clinical significance of Janus Kinase inhibitor selectivity |
19 |
| The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register |
19 |
| Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors |
19 |
| Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data |
19 |
| Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis |
19 |
| Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib |
18 |
| Progress in our understanding of the pathogenesis of ankylosing spondylitis |
17 |
| Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis |
17 |
| Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial |
17 |
| Divergent roles of immune cells and their mediators in pain |
17 |
| European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative |
17 |
| Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register |
17 |
| A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis |
16 |
| The role of fat and inflammation in the pathogenesis and management of osteoarthritis |
16 |
| Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014) |
16 |
| Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis |
15 |
| Management of major organ involvement of Behcet's syndrome: a systematic review for update of the EULAR recommendations |
15 |
| The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies |
15 |
| Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis |
15 |
| Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
15 |
| The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis |
15 |
| Ultrasound in the diagnosis and management of giant cell arteritis |
15 |
| Effect of mechanical stress on magnetic resonance imaging of the sacroiliac joints: assessment of military recruits by magnetic resonance imaging study |
15 |
| Takayasu arteritis: advanced understanding is leading to new horizons |
14 |
| Clinical efficacy of new JAK inhibitors under development. Just more of the same? |
14 |
| The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry |
14 |
| Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome |
14 |
| Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients |
14 |
| Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis |
14 |
| Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis |
14 |
| The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia |
14 |
| The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice |
14 |
| Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis |
13 |
| Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study |
13 |
